Lead sponsor
University Hospital Tuebingen
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
2
Trials led
1
Active
61
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 4
1
Not applicable
1
Trials by status
Recruiting
1
Terminated
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Effect of GLP1 Receptor Agonist on Brain Insulin ResponsivenessBMI 18.5-24.9not applicableRecruiting60